Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.

Typical spherical to oval cells of Cryptococcus neoformans, with extensive capsules and a budding daughter cell © Phan Hai Trieu

The study finds that adding tamoxifen to standard antifungal treatment was no better at speeding up the clearance of fungal infection from the spinal fluid of people with meningitis. More patients who received tamoxifen had evidence of conduction disturbances in their hearts, although there was no difference in the rates of severe side effects between study groups. 

Cryptococcal meningitis is a leading cause of death in people with HIV, but also affects those without HIV, regardless of whether they are immunocompromised. Most infections are caused by a fungus called Cryptococcus neoformans (C. neoformans) and occur in low-income tropical settings. The gold-standard treatment is a combination of three drugs: flucytosine and amphotericin B initially, followed by fluconazole. Yet, even on this gold-standard therapy, a third of patients die within 10 weeks of being diagnosed. Moreover, the drug flucytosine is severely restricted by availability and cost, meaning it is rarely used where the disease burden is highest.

Co-first author Nguyen Thi Thuy Ngan, Clinician at the Department of Tropical Medicine, Cho Ray Hospital, and the Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh City, Vietnam, said: 'Tamoxifen has shown antifungal activity against various yeasts in the lab; we subsequently showed that it acts synergistically with amphotericin against two-thirds of clinical Cryptococcus isolates from our archive. As a well-understood, off-patent, cheap and widely available medicine, it was a promising candidate for treating cryptococcal meningitis.'

Read the full story on the University of Oxford website

Similar stories

New book expands the horizons of brain research

A pioneering book from Professor Zoltán Molnár and Yale Professors Tamas Horvath and Joy Hirsch to be released on 1 February 2022 addresses the fundamental relationship between the body, brain and behaviour.

New research sheds light on how ultrasound could be used to treat psychiatric disorders

A new study in macaque monkeys has shed light on which parts of the brain support credit assignment processes (how the brain links outcomes with its decisions) and, for the first time, how low-intensity transcranial ultrasound stimulation (TUS) can modulate both brain activity and behaviours related to these decision-making and learning processes.

Dramatic fall in hospital admissions for child infections since start of Covid-19 pandemic

Since the onset of the Covid-19 pandemic, there have been dramatic reductions in hospital admissions for common and severe childhood infections in England, most likely due to social distancing measures, school and workplace closures, and travel restrictions, finds a study published by The BMJ today.

Rosalind Franklin Institute and Pharmacology announce strategic partnership in Next Generation Chemistry

The Rosalind Franklin Institute and the University of Oxford’s Department of Pharmacology have entered into a strategic partnership for Next Generation Chemistry.

Christoph Treiber awarded ERC Starting Grant to investigate the origins of behavioural diversity

Congratulations are in order for postdoctoral research scientist Dr Christoph Treiber who has been awarded a Starting Grant from the European Research Council. His funded project will investigate the genetic components that may contribute to diversity of brain function and behaviour.

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.